Viatris expects 2% revenue and EBITDA growth in 2026 as strategic review targets $650M in cost savings
Source: SeekingAlpha
2026-02-26 17:10:08 ET
More on Viatris
- Viatris Inc. (VTRS) Q4 2025 Earnings Call Transcript
- Viatris Inc. 2025 Q4 - Results - Earnings Call Presentation
- Viatris: Deep-Value Pharma With Emerging Growth Catalysts And Strong Cash Generation
- Viatris beats on Q4; eyes 10% staff reduction
- Viatris Non-GAAP EPS of $0.57 beats by $0.04, revenue of $3.7B beats by $170M
Read the full article on Seeking Alpha
For further details see:
Viatris expects 2% revenue and EBITDA growth in 2026 as strategic review targets $650M in cost savings
Viatris Inc.
NASDAQ: VTRS
VTRS Trading
3.0% G/L:
$14.405 Last:
2,636,674 Volume:
$14.17 Open:
VTRS Latest News
February 27, 2026 03:57:23 pm
Bastion Bets on Government Spending with $8 Million New Stake in Parsons
February 26, 2026 06:55:00 am
Viatris Maintains Dividend Policy for 2026 and Announces Quarterly Dividend
VTRS Stock Data
$18,451,353,349
1,140,252,173
N/A
503
N/A
Pharmaceuticals
Healthcare
US
Canonsburg
